SEngine Precision Medicine Revenue and Competitors

Seattle, WA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • SEngine Precision Medicine's estimated annual revenue is currently $3.6M per year.(i)
  • SEngine Precision Medicine's estimated revenue per employee is $155,000

Employee Data

  • SEngine Precision Medicine has 23 Employees.(i)
  • SEngine Precision Medicine grew their employee count by -26% last year.

SEngine Precision Medicine's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Director Clinical OperationsReveal Email/Phone
3
Director, Clinical Consultant, Accreditation, Regulatory, Compliance, CLIA CertifiedReveal Email/Phone
4
Associate Director Cancer Organoid CoreReveal Email/Phone
5
CLIA Laboratory Assistant/Lab ManagerReveal Email/Phone
6
Senior CLIA ScientistReveal Email/Phone
7
Senior Software EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is SEngine Precision Medicine?

SEngine Precision Medicine brings the latest advances in cancer research and treatment to the fight against cancer. With a focus on functional screening, genomics, robotics, cancer organoid cultures, and bioinformatics, SEngine Precision Medicine is providing invaluable data to oncologists and realizing the promise of precise, less toxic and more effective therapies to cancer patients. The accumulation of data is essential to pharmaceutical companies to accelerate the success of cancer treatments. SEngine is CLIA certified to receive your sample today.

keywords:N/A

N/A

Total Funding

23

Number of Employees

$3.6M

Revenue (est)

-26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M235%N/A
#2
$2.9M23-23%N/A
#3
$2.7M23N/AN/A
#4
$4.3M235%N/A
#5
$1.6M235%N/A